Development and Validation of an Analytical Method to Identify and Quantitate Novel Modafinil Analogs in Products Marketed as Dietary Supplements – PubMed Black Hawk Supplements

Abstract

Modafinil (brand name Provigil®) is a Schedule IV (U.S.) drug used for the treatment of narcolepsy and sleep disorders. It is also known to be used recreationally. Analogs of modafinil, including adrafinil, remain unapproved and/or unscheduled. The lack of scheduling has made these analogs a popular target for recreational use and inclusion in dietary supplements. However, the use of controlled substances (or their analogs) without the care of a physician presents a public health risk. Preliminary nontargeted analyses in our laboratory revealed the presence of adrafinil in several dietary supplements, highlighting the need for an analytical method to identify modafinil analogs in supplements. A liquid chromatography high resolution mass spectrometry (LC-HRMS) method was developed and validated to quantitate modafinil, plus four novel unscheduled modafinil analogs: adrafinil, CRL-40,940, CRL-40,941, and N-methyl-4,4-difluoromodafinil. This method was then applied to four samples of products marketed as dietary supplements collected via undercover purchase. These four products were marketed as nootropics or cognitive enhancers and labeled to contain adrafinil. Adrafinil was found in all four samples. The identification of modafinil analogs in this context is important so that consumers are not, knowingly or unknowingly, consuming these active pharmaceutical ingredients in products marketed as dietary supplements.

Keywords: Adrafinil; cognitive enhancers; dietary supplement; modafinil; nootropic.

Similar articles

• Outsmarted by nootropics? An investigation into the thermal degradation of modafinil, modafinic acid, adrafinil, CRL-40,940 and CRL-40,941 in the GC injector: formation of 1,1,2,2-tetraphenylethane and its tetra fluoro analog.

  Dowling G, Kavanagh PV, Talbot B, O’Brien J, Hessman G, McLaughlin G, Twamley B, Brandt SD. Dowling G, et al. Drug Test Anal. 2017 Mar;9(3):518-528. doi: 10.1002/dta.2142. Epub 2016 Dec 29. Drug Test Anal. 2017. PMID: 27928893

• Identification of adrafinil and its main metabolite modafinil in human hair. Self-administration study and interpretation of an authentic case.

  Ameline A, Gheddar L, Raul JS, Kintz P. Ameline A, et al. Forensic Sci Res. 2020 Jan 29;5(4):322-326. doi: 10.1080/20961790.2019.1704482. Forensic Sci Res. 2020. PMID: 33457050 Free PMC article.

• Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects.

  Sousa A, Dinis-Oliveira RJ. Sousa A, et al. Subst Abus. 2020;41(2):155-173. doi: 10.1080/08897077.2019.1700584. Epub 2020 Jan 17. Subst Abus. 2020. PMID: 31951804 Review.

• Effect of modafinil on pancreatic exocrine secretion in rats. A comparison with adrafinil and related drugs.

  Chariot J, Appia F, Vaille C, Rozé C. Chariot J, et al. Fundam Clin Pharmacol. 1987;1(4):243-52. doi: 10.1111/j.1472-8206.1987.tb00563.x. Fundam Clin Pharmacol. 1987. PMID: 2893764

• Unauthorized ingredients in “nootropic” dietary supplements: A review of the history, pharmacology, prevalence, international regulations, and potential as doping agents.

  Jędrejko K, Catlin O, Stewart T, Anderson A, Muszyńska B, Catlin DH. Jędrejko K, et al. Drug Test Anal. 2023 Aug;15(8):803-839. doi: 10.1002/dta.3529. Epub 2023 Jun 25. Drug Test Anal. 2023. PMID: 37357012 Review.